

Appendix Tables

Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma

Shang-Yi Huang, Tsai-Yun Chen, Ching-Yuan Kuo, Yeu-Chin Chen, Sheng-Fung Lin,
Ming-Chih Chang, Xinzhu Lv, Betty Yang, Cheng-Shyong Chang

Non-commercial use only

Table S1. Recommended dose modifications for bortezomib-related neuropathic pain and/or peripheral sensory neuropathy.

Severity of peripheral neuropathy	Modification of dose and regimen
Grade 1 (paresthesia and/or loss of reflexes) with no pain or loss of function	No action
Grade 1 with pain or Grade 2 (interfering with function but no activities of daily living)	Reduce to 1.0 mg/m ²
Grade 2 with pain or Grade 3 (interfering with activities of daily living)	Withhold bortezomib treatment until symptoms of toxicity have resolved When toxicity resolves re-initiate bortezomib treatment and reduce dose to 0.7 mg/m ² and change treatment schedule to once per week
Grade 4 (permanent sensory loss that interferes with function)	Discontinue bortezomib

Table S2 Summary of prior therapy (Safety population).

	Record	Number of patients (%) (N=100)
Radiation therapy, n=17 (17.0%)	22	
CR	0	0 (0.0)
nCR	0	0 (0.0)
PR	2	2 (2.0)
MR	0	0 (0.0)
SD	4	3 (3.0)
PD	0	0 (0.0)
NA/UNK	16	12 (12.0)
Chemotherapy, n=80 (80.0%)	399	
CR	2	1 (1.0)
Thalidomide	1	1 (1.0)
Alkeran	1	1 (1.0)
Velcade	0	0 (0.0)
Lenalidomide	0	0 (0.0)
Other	0	0 (0.0)
nCR	1	1 (1.0)
Alkeran	1	1 (1.0)
Velcade	0	0 (0.0)
Lenalidomide	0	0 (0.0)
Other	0	0 (0.0)
PR	6	3 (3.0)
Thalidomide	4	3 (3.0)
Alkeran	2	2 (2.0)
Velcade	0	0 (0.0)
Lenalidomide	0	0 (0.0)
Other	0	0 (0.0)
MR	0	0 (0.0)
SD	0	0 (0.0)
PD	8	4 (4.0)
Thalidomide	2	2 (2.0)
Alkeran	2	2 (2.0)
Velcade	1	1 (1.0)

Lenalidomide	2	1 (1.0)
Other	1	1 (1.0)
NA/UNK	382	78 (78.0)
Hormone therapy, n=77 (77.0%)	314	
CR	1	1 (1.0)
nCR	1	1 (1.0)
PR	5	3 (3.0)
MR	1	1 (1.0)
SD	0	0 (0.0)
PD	6	3 (3.0)
NA/UNK	300	74 (74.0)
Immunotherapy, n=8 (8.0%)	18	
CR	0	0 (0.0)
nCR	0	0 (0.0)
PR	0	0 (0.0)
MR	0	0 (0.0)
SD	0	0 (0.0)
PD	0	0 (0.0)
NA/UNK	18	8 (8.0)
Biologic therapy, n=1 (1.0%)	10	
CR	0	0 (0.0)
nCR	0	0 (0.0)
PR	0	0 (0.0)
MR	0	0 (0.0)
SD	0	0 (0.0)
PD	0	0 (0.0)
NA/UNK	10	1 (1.0)
Other therapy, n=2 (2.0%)	2	
CR	0	0 (0.0)
nCR	0	0 (0.0)
PR	0	0 (0.0)
MR	0	0 (0.0)
SD	0	0 (0.0)
PD	0	0 (0.0)
NA/UNK	2	2 (2.0)

CR, Complete response; NA/UNK, Not available/Unknown; nCR, Near complete response; MR, Minimal response, ORR, Overall response rate; OS, Overall survival; PR, Partial response; SD, Stable disease; VGPR, Very good partial response.